Synthorx is developing a pipeline of Synthorin™ cytokines, including an IL-2 tuned specifically for activity on certain immune cells. Using the company’s expanded genetic alphabet technology based on a breakthrough in synthetic biology from Scripps Research, Synthorin cytokines are designed to selectively tune receptor pharmacology and extend half-life. These properties allow for efficacious immune system activation with convenient dosing schedules and without safety limitations to enhance the antitumor activity of leading immuno-oncology approaches, including checkpoint inhibitors, cancer vaccines, CAR-T therapies, and oncolytic viruses. NASDAQ: THOR